Ispecimen INC 10-Q quarterly reports

iSpecimen Inc. reported a significant 76% revenue decrease for the nine months ended September 30, 2025, alongside a reduced net loss and successful capital raises, but faces ongoing legal challenges and a 'going concern' warning.

iSpecimen Inc. reported a 66% revenue drop and worsening working capital for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite significant cost reductions and recent capital raises.

iSpecimen Inc.'s Q1 2025 revenue decreased by 54% year-over-year, while the company continued to implement cost-cutting measures and address a material weakness in internal controls.

iSpecimen Inc. reported a slight decrease in revenue for Q3 2024, alongside significant reductions in operating expenses and a net loss improvement compared to the same period last year.

iSpecimen Inc. saw a significant increase in revenue during the second quarter of 2024, but ongoing losses and negative working capital raise concerns about the company's ability to continue as a going concern.

iSpecimen Inc. reported a decrease in revenue for the first quarter of 2024, alongside ongoing cost-cutting measures and a focus on new revenue enhancement projects.